期刊文献+
共找到8篇文章
< 1 >
每页显示 20 50 100
晚期胃癌一线免疫治疗的现状与进展 被引量:4
1
作者 姜志超(综述) 周爱萍(审校) 《中国肿瘤临床》 CAS CSCD 北大核心 2023年第4期206-211,共6页
晚期胃癌预后较差,传统化疗疗效有限,未能满足患者治疗需求。免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)已改变晚期胃癌治疗格局,其中程序性死亡受体-1(programmed death-1,PD-1)抑制剂联合化疗、PD-1抑制剂联合曲妥珠单抗... 晚期胃癌预后较差,传统化疗疗效有限,未能满足患者治疗需求。免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)已改变晚期胃癌治疗格局,其中程序性死亡受体-1(programmed death-1,PD-1)抑制剂联合化疗、PD-1抑制剂联合曲妥珠单抗及化疗已分别成为人表皮生长因子受体2(human epidermal growth factor receptor 2,HER-2)阴性或阳性晚期胃癌一线治疗选择,其他免疫检查点分子抑制剂和癌症疫苗、过继性细胞输注等疗法的研究均在进行中。如何通过生物标志物筛选免疫治疗最佳获益人群,是近期研究热点。除肿瘤突变负荷、程序性死亡配体-1(programmed death-ligand 1,PD-L1)表达、微卫星不稳定性等,新兴标志物如循环肿瘤DNA、肠道微生物组学和细胞因子等均值得关注。本文就晚期胃癌一线免疫治疗的临床研究进展及展望进行综述。 展开更多
关键词 胃癌 免疫检查点抑制剂 生物标志物
下载PDF
FOLFOXIRI改良方案一线治疗晚期胃癌疗效及安全性分析 被引量:12
2
作者 姜志超 张雯 +3 位作者 孙永琨 杨林 崔成旭 周爱萍 《中国肿瘤临床》 CAS CSCD 北大核心 2020年第9期438-441,共4页
目的:分析FOLFOXIRI改良方案一线治疗晚期胃癌的疗效及安全性。方法:选取2016年7月至2019年3月于中国医学科学院肿瘤医院采用FOLFOXIRI改良方案一线治疗的晚期胃癌20例。药物用法:奥沙利铂85 mg/m2静点d1,伊立替康120 mg/m2静点d1,亚叶... 目的:分析FOLFOXIRI改良方案一线治疗晚期胃癌的疗效及安全性。方法:选取2016年7月至2019年3月于中国医学科学院肿瘤医院采用FOLFOXIRI改良方案一线治疗的晚期胃癌20例。药物用法:奥沙利铂85 mg/m2静点d1,伊立替康120 mg/m2静点d1,亚叶酸钙200 mg/m2静点d1,氟尿嘧啶2400 mg/m2持续静点44 h,每14天为1个周期。主要终点为客观缓解率(objective response rate,ORR)。次要终点包括无进展生存时间(progression free survival,PFS)、总生存时间(overall survival,OS)、疾病控制率(disease control rate,DCR)、缓解持续时间(duration of response,DOR)、安全性。结果:中位治疗8个周期,ORR为50%,DCR为95%。中位起效时间为1.6个月,中位DOR为8.7个月。中位随访时间19.5个月,中位PFS为9.5个月(95%CI:7.309~11.691),中位OS为19.9个月(95%CI:9.754~30.046)。常见不良反应包括中性粒细胞减少、肝功能异常、腹泻等。主要3级不良反应为中性粒细胞减少(50%)、腹泻(10%)、ALT升高(10%),无≥4级不良反应。结论:降低伊立替康剂量的FOLFOXIRI改良方案在晚期胃癌一线治疗中初步显示出良好的疗效和耐受性,值得进一步开展临床研究。 展开更多
关键词 胃癌 伊立替康 奥沙利铂 氟尿嘧啶 化疗
下载PDF
Causal Inference 被引量:8
3
作者 Kun Kuang Lian Li +7 位作者 Zhi Geng Lei Xu Kun Zhang Beishui Liao Huaxin Huang Peng Ding Wang Miao zhichao jiang 《Engineering》 SCIE EI 2020年第3期253-263,共11页
Causal inference is a powerful modeling tool for explanatory analysis,which might enable current machine learning to become explainable.How to marry causal inference with machine learning to develop explainable artifi... Causal inference is a powerful modeling tool for explanatory analysis,which might enable current machine learning to become explainable.How to marry causal inference with machine learning to develop explainable artificial intelligence(XAI)algorithms is one of key steps toward to the artificial intelligence 2.0.With the aim of bringing knowledge of causal inference to scholars of machine learning and artificial intelligence,we invited researchers working on causal inference to write this survey from different aspects of causal inference.This survey includes the following sections:“Estimating average treatment effect:A brief review and beyond”from Dr.Kun Kuang,“Attribution problems in counterfactual inference”from Prof.Lian Li,“The Yule–Simpson paradox and the surrogate paradox”from Prof.Zhi Geng,“Causal potential theory”from Prof.Lei Xu,“Discovering causal information from observational data”from Prof.Kun Zhang,“Formal argumentation in causal reasoning and explanation”from Profs.Beishui Liao and Huaxin Huang,“Causal inference with complex experiments”from Prof.Peng Ding,“Instrumental variables and negative controls for observational studies”from Prof.Wang Miao,and“Causal inference with interference”from Dr.Zhichao Jiang. 展开更多
关键词 Causal inference Instructive variables Negative control Causal reasoning and explanation Causal discovery Counterfactual inference Treatment effect estimation
下载PDF
晚期结直肠癌三药联合方案化疗的研究进展 被引量:8
4
作者 姜志超 张雯(综述) 周爱萍(审校) 《中国肿瘤临床》 CAS CSCD 北大核心 2021年第4期201-205,共5页
化疗是晚期结直肠癌(colorectal cancer,CRC)的主要治疗手段。FOLFOXIRI三药联合方案(奥沙利铂+伊立替康+氟尿嘧啶)一线治疗晚期CRC较氟尿嘧啶单药或FOLFOX(奥沙利铂+氟尿嘧啶)、FOLFIRI(伊立替康+氟尿嘧啶)等两药联合方案可显著延长患... 化疗是晚期结直肠癌(colorectal cancer,CRC)的主要治疗手段。FOLFOXIRI三药联合方案(奥沙利铂+伊立替康+氟尿嘧啶)一线治疗晚期CRC较氟尿嘧啶单药或FOLFOX(奥沙利铂+氟尿嘧啶)、FOLFIRI(伊立替康+氟尿嘧啶)等两药联合方案可显著延长患者的无进展生存(progression free survival,PFS)及总生存期(overall survival,OS),是晚期CRC标准治疗方案之一。三药联合方案或联合贝伐珠单抗具有更高的客观缓解率(objective response rate,ORR)及R0切除率,可作为晚期CRC转化治疗方案。对于RAS/RAF野生型CRC,FOLFOXIRI方案联合表皮生长因子受体(epidemal growth factor receptor,EGFR)单抗亦具有较好的ORR,有望成为晚期CRC又一转化治疗方案,但目前循证医学证据尚不充分。三药联合方案获益患者治疗进展后,再挑战原方案或选择两药联合方案仍可带来生存获益。虽然FOLFOXIRI方案疗效显著,但鉴于其安全性及耐受性,临床应用中仍存在问题亟需进一步探讨。本文对FOLFOXIRI三药联合方案的治疗价值、临床应用、方案改良等方面进行分析与探讨,并同时回顾FOLFOXIRI方案在晚期CRC中的应用及发展。 展开更多
关键词 结直肠癌 三药联合治疗化疗 FOLFOXIRI方案
下载PDF
Spatial heterogeneity and source apportionment of soil metal(loid)s in an abandoned lead/zinc smelter 被引量:5
5
作者 Yunxia Zhang Tianshuang Li +5 位作者 Zhaohui Guo Huimin Xie Zhihao Hu Hongzhen Ran Changzhou Li zhichao jiang 《Journal of Environmental Sciences》 SCIE EI CAS CSCD 2023年第5期519-529,共11页
Metal smelting have brought severe metal(loid)s contamination to the soil.Spatial distribution and pollution source analysis for soil metal(loid)s in an abandoned lead/zinc smelter were studied.The results showed that... Metal smelting have brought severe metal(loid)s contamination to the soil.Spatial distribution and pollution source analysis for soil metal(loid)s in an abandoned lead/zinc smelter were studied.The results showed that soil was contaminated heavily withmetal(loid)s.The mean of lead(Pb),arsenic(As),cadmium(Cd),mercury(Hg)and antimony(Sb)content in topsoil is 9.7,8.2,5.0,2.3,and 1.2 times higher than the risk screening value for soil contamination of development land of China(GB36600-2018),respectively.Cd ismainly enriched in the 0–6mdepth of site soil while As and Pbmainly deposited in the 0–4mlayer.The spatial distribution of soil metal(loid)s is significantly correlated with the pollution source in the different functional areas of smelter.As,Hg,Sb,Pb and copper(Cu)were mainly distributed in pyrometallurgical area,while Cd,thallium(Tl)and zinc(Zn)was mainly existed in both hydrometallurgical area and raw material storage area.Soil metal(loid)s pollution sources in the abandoned smelter are mainly contributed to the anthropogenic sources,accounting for 84.5%.Specifically,Pb,Tl,As,Hg,Sb and Cumainly from atmospheric deposition(55.9%),Cd and Zn mainly from surface runoff(28.6%),While nickel(Ni)mainly comes from parent material(15.5%).The results clarified the spatial distribution and their sources in different functional areas of the smelter,providing a new thought for the risk prevention and control of metal(loid)s in polluted site soil. 展开更多
关键词 Smelting industry Site soil Metal(loid)s Spatial heterogeneity Source apportionment
原文传递
Nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule (S-1) as first-line treatment for advanced biliary tract adenocarcinoma: a phase 2 clinical trial
6
作者 Wen Zhang Yongkun Sun +3 位作者 zhichao jiang Wang Qu Caifeng Gong Aiping Zhou 《Hepatobiliary Surgery and Nutrition》 SCIE 2023年第1期37-44,共8页
Background:This study aimed to evaluate the efficacy and safety of a new combination of nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule(S-1)for patients with advanced biliary tract carcinoma(BTC).Meth... Background:This study aimed to evaluate the efficacy and safety of a new combination of nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule(S-1)for patients with advanced biliary tract carcinoma(BTC).Methods:Patients were treated with nab-paclitaxel at a dose of 125 mg/m2 on day 1 and 8,and S-1,80 to 120 mg/day on days 1-14 of a 21-day cycle.Treatments were repeated until disease progression or unacceptable toxicity occurred.The primary endpoint was objective response rate(ORR).The secondary endpoints were median progression-free survival(PFS),overall survival(OS),and adverse events(AEs).Results:The number of patients enrolled were 54,and 51 patients were evaluated for efficacy.A total of 14 patients achieved partial response(PR)with an ORR of 27.5%.The ORR varied by sites,with 53.8%(7/13)for gallbladder carcinoma,18.4%(7/38)for cholangiocarcinoma.The most common grade 3 or 4 toxicities were neutropenia and stomatitis.The median PFS and OS were 6.0 and 13.2 months,respectively.Conclusions:The combination of nab-paclitaxel with S-1 showed explicit antitumor activities and favorable safety profile in advanced BTC and could serve as a potential non-platinum and-gemcitabine-based regimen. 展开更多
关键词 Biliary tract adenocarcinoma chemotherapy NAB-PACLITAXEL tegafur gimeracil oteracil potassium capsule(S-1)
原文传递
Bifurcation analysis of modeling biodegradation of Microcystins
7
作者 Keying Song Wanbiao Ma zhichao jiang 《International Journal of Biomathematics》 SCIE 2019年第3期91-108,共18页
In this paper, a model with time delay describing biodegradation of Microcystins (MCs) is investigated. Firstly, the stability of the positive equilibrium and the existence of Hopf bifurcations are obtained. Furthermo... In this paper, a model with time delay describing biodegradation of Microcystins (MCs) is investigated. Firstly, the stability of the positive equilibrium and the existence of Hopf bifurcations are obtained. Furthermore, an explicit algorithm for determining the direction and the stability of the bifurcating periodic solutions is derived by using the normal form theory and center manifold argument. Finally, some numerical simulations are carried out to illustrate the applications of the results. 展开更多
关键词 MICROCYSTINS BIODEGRADATION STABILITY HOPF BIFURCATION PERMANENCE
原文传递
STABILITY ANALYSIS OF A PREDATOR-PREY MODEL
8
作者 zhichao jiang ZHAOZHUANG GUO YUEFANG SUNS 《International Journal of Biomathematics》 2012年第1期89-102,共14页
关键词 稳定性分析 捕食模型 HOPF分岔 中心流形理论 捕食系统 时间延迟 显式算法 数值模拟
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部